Mycoplasma Pneumonia
5
0
0
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
5 treatments under study, led by Liaison Nes Flu Ab Rsv Covid19
Research Leaders
5 sponsors active, led by University Children's Hospital, Zurich
Related Conditions
Often studied with 17 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 5 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (5)
LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia
Evaluation of Pathogenesis and Diagnosis of Mycoplasma Pneumoniae Community-acquired Pneumonia (CAP)
Etiology of Community Acquired Pneumonia
The Optimization of Mycoplasm Pneumonia Antibiotic Therapy
Prevalence and Clinical Significance of Co-infection of Mycoplasma Pneumoniae in Patients With Pulmonary Tuberculosis
Research Network
Common Treatments
- Liaison Nes Flu Ab Rsv Covid191
- Cephalosporins And Azithromycin1
- Enzymelinked Immunospot Elispot Assay Blood1
- Moxifloxacin1
- Liaison Plex Respiratory Flex Assay1
Active Sponsors
- University Children's Hospital, Zurich1
- DiaSorin Molecular LLC1
- Seoul National University Hospital1
- Capital Medical University1
- University of Pittsburgh1
Top Investigators
DiaSorin Molecular/Luminex Corporation
University Children's Hospital, Zurich
Seoul National University Hospital
Capital Medical University affiliated Beijing Chaoyang Hospital, Beijing Respiratory Medicine Insititute
University of Pittsburgh/University of Pittsburgh Medical Center
Related Conditions
- Chlamydia Pneumonia2
- Antibodysecreting Cells1
- Diagnosis1
- Bordetella Parapertussis Infection1
- Bordetella Pertussis Infection Respiratory1